Kiri Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-06-2024
- Paid Up Capital ₹ 0.10 M
as on 29-06-2024
- Company Age 9 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2021)
- Profit -18.48%
(FY 2021)
- Ebitda -337.50%
(FY 2021)
- Net Worth -8.33%
(FY 2021)
- Total Assets -4.35%
(FY 2021)
About Kiri Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Arunaben Kiri and Amisha Kiri serve as directors at the Company.
- CIN/LLPIN
U24230GJ2015PTC082161
- Company No.
082161
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 2015
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Kiri Laboratories Private Limited offer?
Kiri Laboratories Private Limited offers a wide range of products and services, including Eye Cosmetic, Eye Shadow, Cosmetics, Cosmetic Third Party Manufacturing, Chemical Reagents & Catalysts, Inorganic Salts, Industrial Chemicals & Supplies, Biocides, Body Powder, Compact Powder.
Who are the key members and board of directors at Kiri Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arunaben Kiri  | Director | 06-Feb-2015 | Current |
| Amisha Kiri | Director | 03-Jan-2018 | Current |
Financial Performance and Corporate Structure Insights of Kiri Laboratories.
Kiri Laboratories Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 18.48% decrease in profit. The company's net worth dipped by a decrease of 8.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kiri Laboratories?
In 2018, Kiri Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kiri Laboratories?
Unlock and access historical data on people associated with Kiri Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kiri Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kiri Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
